Advertisement
Aqilion resumes development of its TAK1-program

The company has resumed development of the its TAK1 program as the company has regained the control and ownership of the program.
After reviewing and analyzing the complete data package, Aqilion decided to recommence the development of the program.
“We are pleased and excited to continue our preclinical TAK1 program, since it is a highly interesting drug target in several chronic inflammation and autoimmune diseases. The analysis of all data, generated internally and externally, encouraged us to resume the development. We are looking forward to presenting the program during partnering meetings later this year,” says Sarah Fredriksson, CEO of Aqilion.
The TAK1 mechanism is a key regulator of inflammation and the objective is to develop a new treatment for severe diseases caused by chronic inflammation and dysfunctional immune reactions. The TAK1 mechanism is a central biological switch for several central inflammatory processes. By dampening its activity, there is potential to block and delay progression in severe and chronic diseases. The target has been identified as a key mechanism by academia and industry, and there is widespread interest in its potential in a number of indications.
Based on proprietary data in combination with data and knowledge generated in collaboration with Merck KGaA during 2023 -2024.
Aqilion’s internal drug development has led to unique small molecule inhibitors and the collaboration with Merck KGaA further added new molecular assets. The new project strategy for the TAK1 program is based on proprietary data in combination with data and knowledge generated in collaboration with Merck KGaA during 2023 -2024.
Published: February 5, 2025
Advertisement